Drost, C.C., Rovas, A., Kusche-Vihrog, K., Van Slyke, P., Kim, H., Hoang, V.C., Maynes, J.T., Wennmann, D.O., Pavenstädt, H., Linke, W. and Lukasz, A., 2019. Thrombosis and haemostasis, 119(11), pp.1827-1838.
About
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.